Risdiplam (Evrysdi®)
Risdiplam (Evrysdi®) is used in the treatment of 5q-Spinal Muscular Atrophy (SMA). A Managed Access Protocol (MAP) is in place for Risdiplam (Evrysdi®). This outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of Risdiplam under the High Tech Arrangement.
The prescribing of Risdiplam under the High Tech Arrangement will only be considered from consultant neurologists or consultant paediatricians with a special interest in neurology, with specialist registration with the Irish Medical Council in the specialities of neurology or paediatrics, who have experience in the diagnosis and management of SMA and are practicing in specialist centre(s) in Ireland, and who have agreed to the terms of this MAP and have been approved by the HSE (‘approved consultants’).
The clinician must submit an application for individual reimbursement approval for each patient. Applications for individual reimbursement approval will only be considered from approved consultants.
A copy of the HSE-Managed Access Protocol for Risdiplam and the application form for individual reimbursement approval can be found in the Related Files section below.
For further information, please contact mmp@hse.ie
Data Snapshot on treatments for SMA